Alkeus Pharmaceuticals Appoints Seemi Khan, M.D., Chief Medical Officer
CAMBRIDGE, Mass., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc. today announced that Seemi Khan, M.D., M.P.H., M.B.A., has...
Pharmaceutical
Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12’s Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy
SOLANA BEACH, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling...
Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
REDWOOD CITY, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative...
Recce Pharmaceuticals Reports Positive Phase I/II Trial Results of RECCE® 327 for the Treatment of Diabetic Foot Infections
Phase I/II trial assessing the safety and efficacy of RECCE® 327 (R327), a broad-spectrum anti-infective as a topical treatment, met...
NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber’s Hereditary Optic Neuropathy (LHON)
NAYA to accelerate Phase II clinical development and Early Patient Access after initial safety demonstrated in 28-patient clinical trialProgram developed...
Pressure BioSciences Announces Closing of Uncle Bud’s Acquisition in All-Stock Transaction, Completing UltraShear Nanoemulsions Forward Integration with World Class Marketing & Sales
Merged Companies Will Introduce Revolutionary New Product Capabilities Across Multiple Major Market Sectors, Expecting 2024 Revenues of Over $10 Million,...
Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024...
ORIC Pharmaceuticals Announces $125 Million Private Placement Financing
Funding from new and existing investors including Viking Global Investors, Commodore Capital, Frazier Life Sciences, Venrock Healthcare Capital Partners, New...
RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of Directors
Glen Rock, N.J., Jan. 22, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market:RSPI) (“RespireRx” or the “Company”), a...
Lumanity Reorganizes and Expands Strategic Consulting Capabilities
Lumanity Reorganizes and Expands Strategic Consulting Capabilities Realigning global, clinical, regulatory, medical, and commercial consulting expertise to facilitate life science...
Biora Therapeutics Announces Participation in Fireside Chat Hosted by H.C. Wainwright & Co.
SAN DIEGO, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic...
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for...
Evotec SE: Invitation to Conference Call
HAMBURG, GERMANY / ACCESSWIRE / January 22, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) is going...
ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024
MADRID, Spain and BOSTON, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical...
MangoRx’s Brand and Products to be Featured by Barstool Sports in Week of Programming Around the Biggest Sports Event of the Year on February 11
"King of the Internet" Dave Portnoy's Uber-Popular Sports Media Company to Spotlight FDA-Approved Oral Testosterone Replacement ‘Prime’ by MangoRx, Powered...
Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer
FDA and Processa agree to expand NGC-Cap development into breast cancer providing a more efficient path to approval FDA agrees...
Optimi Health Secures Amendment to Increase Quantities Of MDMA, MDA, And 2C-B Under Controlled Drugs And Substances Dealer’s Licence
Strategic licensing plan prepares Company for future regulatory approvalsVANCOUVER, British Columbia, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp....
Cresemba® sales in Latin America trigger first sales milestone payment to Basilea
Allschwil, Switzerland, January 19, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs...
United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease
REVASCOR Increases Size of Left Heart Chamber and Improves Surgical Outcomes in Children with Hypoplastic Left Heart Syndrome: Results Published...
GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression
DUBLIN, Ireland, Jan. 18, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming...